Evidence map›Paper›PMID 42089455›Full record

ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026

CD44-Targeting Hydroxyapatite Nanoparticles (HAP) Induce Mitochondrial Dysfunction-Driven PANoptosis and Immunogenic Cell Death (ICD) via Ca Overload in Colorectal Cancer.

Yao Xiao, Yuxuan Yang, Haosen Qiu, Jia Yang, Hao Liang, Zhaojun Jiang, Xiao Tong, Yongying Li, Qunfeng Huang, Jiaming Wu and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Yao XiaoDepartment of Oncology, Department of Oncology, GuangDong Engineering Technology Research Center of Biological Targeting Diagnosis, Therapy and Rehabilitation, The Fifth Affiliated Hospital, Guangzhou Medical University, Guangzhou, China.
Yuxuan YangDepartment of General Surgery, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Haosen QiuDepartment of General Surgery, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Jia YangDepartment of General Surgery, Xiangyang Central Hospital, Affiliated Hospital of Hubei University of Arts and Science, Xiangyang, China.
Hao LiangDepartment of Oncology, Department of Oncology, GuangDong Engineering Technology Research Center of Biological Targeting Diagnosis, Therapy and Rehabilitation, The Fifth Affiliated Hospital, Guangzhou Medical University, Guangzhou, China.
Zhaojun JiangDepartment of Oncology, Department of Oncology, GuangDong Engineering Technology Research Center of Biological Targeting Diagnosis, Therapy and Rehabilitation, The Fifth Affiliated Hospital, Guangzhou Medical University, Guangzhou, China.
Xiao TongDepartment of Respiratory and Critical Care Medicine, Key Laboratory of Biological Targeting Diagnosis, Therapy and Rehabilitation of Guangdong Higher Education Institutes, The Fifth Affiliated Hospital, Guangzhou Medical University, Guangzhou, China.
Yongying LiDepartment of Oncology, Department of Oncology, GuangDong Engineering Technology Research Center of Biological Targeting Diagnosis, Therapy and Rehabilitation, The Fifth Affiliated Hospital, Guangzhou Medical University, Guangzhou, China.
Qunfeng HuangDepartment of Oncology, Department of Oncology, GuangDong Engineering Technology Research Center of Biological Targeting Diagnosis, Therapy and Rehabilitation, The Fifth Affiliated Hospital, Guangzhou Medical University, Guangzhou, China.
Jiaming WuDepartment of Gastrointestinal Surgery, Affiliated Hospital of Jiaxing University, Jiaxing, China.
Tian LinDepartment of General Surgery, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Jiang YuDepartment of General Surgery, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Min LiangDepartment of Oncology, Department of Oncology, GuangDong Engineering Technology Research Center of Biological Targeting Diagnosis, Therapy and Rehabilitation, The Fifth Affiliated Hospital, Guangzhou Medical University, Guangzhou, China.

Funding

Graduate Research Project of Guangzhou Municipal Education Bureau 2024312340Guangzhou Major Medical Disciplines Project 2025-2027Guangzhou Medical University Innovation ability improvement plan project 02-408-240603131121Guangzhou Municipal Health Science and Technology General Guidance Project 20261A010109Jiaxing Key Discipline of Traditional Chinese Medicine Surgery 2023-ZYYCX-002National Oncology Clinical Key Speciality 2023-GJZK-001Technology Program of Zhejiang Province 2025KY348Xiangyang Central Hospital Youth Talent Development Program 2025RCYC-013
6 · The paper itself

Abstract

Colorectal cancer (CRC) remains therapeutically challenging due to high metastasis, recurrence, and immunotherapy resistance driven by tumor microenvironment-mediated immune evasion. Immunogenic cell death (ICD) offers a promising strategy to reshape the immune microenvironment, yet existing ICD inducers suffer from poor targeting efficiency and insufficient death signal release. Here, we constructed a calcium overload-based smart nanosystem, HA-HAP@CUR, to achieve highly efficient ICD induction via a triple-effect mechanism: hyaluronic acid (HA)-mediated CD44 targeting enables tumor-selective accumulation; pH-responsive hydroxyapatite (HAP) degradation releases Ca

Indexed as

CalciumColorectal NeoplasmsDurapatiteHyaluronan ReceptorsImmunogenic Cell DeathMitochondriaNanoparticlesAnimalsCell Line, TumorHumansMiceTumor MicroenvironmentCalciumDurapatiteHyaluronan Receptorscalcium overloadcolorectal cancerimmunogenic cell deathimmunotherapyPANoptosis

Identifiers

PMID42089455
PMCPMC13335995

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.